External validation of prognostic and

predictive gene signatures in head and 2

neck cancer patients 3

- Erlend I. F. Fossen^{1,2,*}, Mauricio Moreira-Soares¹, Marissa LeBlanc^{1,3}, Arnoldo Frigessi¹, 5
- Eivind Hovig^{4,5}, Laura Lopez-Perez⁶, Estefanía Estévez-Priego⁶, Liss Hernandez⁶, Maria 6
- Fernanda Cabrera-Umpierrez⁶, Giuseppe Fico⁶, Ingeborg Tinhofer⁷, Vanessa Sachse⁷, 7
- Kathrin Scheckenbach⁸, Christophe Le Tourneau⁹, Maud Kamal⁹, Steve Thomas¹⁰, Miranda 8
- Pring¹⁰, Lisa Licitra^{11,12}, Loris De Cecco¹³, Stefano Cavalieri^{11,12} 9
- ¹Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences, 11
- University of Oslo, Oslo, Norway 12
- ² CICERO Center for International Climate Research, Oslo, Norway 13
- ³ Department of Method Development and Analytics, Norwegian Institute of Public Health, 14
- Oslo, Norway 15

1

4

10

- ⁴ Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway 16
- ⁵ Department of Tumor biology, Institute for Cancer Research, Oslo University Hospital, 17
- 18 0310 Oslo, Norway
- ⁶ Universidad Politécnica de Madrid-Life Supporting Technologies Research Group, ETSIT, 19
- 28040 Madrid, Spain 20
- ⁷ Department of Radiooncology and Radiotherapy, Translational Radiation Oncology 21
- Research Laboratory, Charité Universitätsmedizin Berlin, corporate member of Freie 22
- Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117 Berlin, 23
- 24 Germany

35

38

- ⁸ Heinrich-Heine-Universität Düsseldorf, Dusseldorf, Germany 25
- ⁹ Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay 26
- University, Paris, France 27
- ¹⁰ Bristol Dental School, University of Bristol, United Kingdom 28
- ¹¹ Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei 29
- Tumori di Milano, via Giacomo Venezian 1, 20133 Milan, Italy 30
- ¹² Department of Oncology and Hemato-oncology, University of Milan, via Santa Sofia 9/1, 31
- 20122 Milan, Italy 32
- ¹³ Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Giacomo 33
- Venezian 1, 20133 Milan, Italy 34
- *Corresponding author, erlend.fossen@cicero.oslo.no 36
- § Stefano Cavalieri and Loris De Cecco equally contributed as co-last authors. 37

Abstract

40

53

54

62

78

- Head and neck squamous cell carcinomas (HNSCC) are aggressive and heterogenous tumors 41
- with a high fatality rate. Many gene signatures (GS) have been developed with both 42
- prognostic and predictive significance. We aimed to externally validate five published GS in 43
- a large European collection of HNSCC patients. Gene expression from 1097 treatment-naïve 44
- HNSCC patients' primary tumors was used to calculate scores for the five GS. Cox 45
- proportional hazard models were used to test the association between both 2-year overall 46
- survival and 2-year disease-free survival and the signature scores. The predictive role of GS 47
- 48 was validated by comparing survival associations in patients receiving specific treatment (i.e.,
- radiotherapy, systemic treatment) versus those who did not. We successfully externally 49
- 50 validated all 5 GS, including two prognostic signatures, one signature as prognostic and
- 51 predictive of sensitivity to systemic treatment, while signatures for cisplatin-sensitivity and
- radiosensitivity were validated as prognostic only. 52

1. Introduction

- Head and neck cancer (HNC) is the 7th most common cancer worldwide, with more than 55
- 890,000 new cases and 450,000 deaths annually^{1,2}. Head and neck squamous cell carcinoma 56
- (HNSCC) is the most common histological type of HNC, making up 90% of all HNC 57
- 58 cases^{2,3}, roughly 4.5% of all global cancer diagnoses and approximately 4.6% of all cancer
- deaths^{1,2}. Major risk factors for HNSCC are tobacco smoking and alcohol consumption^{1,3}, but 59
- human papillomavirus (HPV) infection is also a known risk factor for oropharyngeal 60
- cancers⁴. 61
- HNSCCs are a heterogenous group of cancers with malignancies developing at various 63
- anatomical sub-sites and with high molecular tumor heterogeneity^{5,6}. This heterogeneity 64
- contributes to differences between patients in terms of treatment response with a need for 65
- personalized approaches^{6,7}. In general, HNSCC patients with early disease (stage I-II) have 66
- high cure rates with single modality therapies (either surgery or radiotherapy). Subjects with 67
- 68 loco-regionally advanced disease (stage III-IVa/b) are treated with multimodal approaches
- (i.e., various combinations of surgery, radiotherapy and systemic treatment)⁸. Despite optimal 69
- treatments, approximately half of patients develop recurrence within 2 years and half die with 70
- disease within 5 years from the diagnosis⁹. Reliable biomarkers and gene signatures (GS) are 71
- crucial for developing personalized treatment 10,11. GS are sets of genes involved in a 72
- biological process that can provide information about the expected disease outcome 73
- (prognostic) and/or the response to a specific treatment (predictive)^{10,11}. Prognostic signatures 74
- provide information about disease prognosis irrespective of therapy. Meanwhile, predictive 75
- signatures inform about how likely a patient is to respond to a specific therapy and can 76
- 77 therefore enable more personalized treatment plans.
- Many prognostic GS, calculated from gene expression in treatment-naïve tumors, have been 79
- developed for HNSCC^{12–16}. External validation of already published GS is an important step 80
- towards incorporating GS in clinical practice¹⁷. In this study, we decided to consider only GS 81
- which were already published, and which were either disease- or treatment-specific. Among 82
- them is a 172-gene signature ¹⁸ (172-GS) that was developed to be prognostic of patient's risk 83

perpetuity.

It is made available under a CC-BY-NC 4.0 International license .

of relapse in HNSCC patients independently of HPV-status, but was later shown to not be prognostic of overall survival (OS) in HPV-positive patients¹⁹. However, in the same patient population, a specific three-cluster HPV signature²⁰ (3 clusters HPV) was developed and externally validated as prognostic of OS¹⁹. As for predictive signatures, the 10-gene radiosensitivity index²¹ (RSI) is among the most validated pan-cancer GSs for prediction of sensitivity to radiotherapy²². Another pan-cancer predictive signature, in this case predictive of cisplatin-sensitivity²³ (pancancer-cisplatin), was recently developed, but has not been externally validated in HNSCC patients. Lastly, a signature that classifies HNC patients into six different subtypes/clusters was developed by De Cecco et al²⁴. One of them (Cl3-hypoxia) showed hypoxic features and was found to be prognostic^{19,25} and related to response to treatment with anti-EGFR agents (cetuximab and afatinib)^{26,27}.

Using a large collection of HNSCC patients with available gene expression data, we aimed to externally validate two prognostic gene signatures (172-GS and 3 clusters HPV), two predictive gene signatures (RSI and pancancer-cisplatin) and one prognostic and predictive GS (Cl3-hypoxia). In contrast to earlier studies, we wanted to explicitly test whether the prognostic signatures (172-GS and 3 clusters HPV) are valid independent of HPV-status, and explicitly test if the predictive signatures are predictive of treatment response by comparing if the signature effect is only found in patients with a specific treatment and not in patients without that treatment. We tested these signatures using two survival endpoints, OS and disease-free survival (DFS).

2. Methods

84

85

86

87

88

89

90

91

92

93

94 95 96

97

98

99 100

101

102

103

104105

106

107

123

124

2.1. Ethics statement

- This study was conducted in full accordance with the World Medical Association's
- Declaration of Helsinki (2013 version). The protocol was ethically approved by the
- Norwegian Regional Committee for Medical and Health Research Ethics (REK) South-East
- 111 A under application number 270467. The data is securely stored in the University of Oslo's
- server for sensitive data (TSD/USIT), adhering to the requirements of GDPR legislation.
- 113 Access to the data is granted only to authorized collaborators who have been included in the
- ethical approval. All proprietary studies that contributed data obtained ethical approval from
- their respective local authorities in Italy, Germany, or France. Copies of these ethical
- approvals were provided to the principal investigator by the data providers. BD2Decide was
- approved by the Ethical Committee of the Fondazione IRCCS Istituto Nazionale dei Tumori
- (Milan, Italy) in 2016 and it has two identifiers: INT65-16 and INT66-16. Biomarker analysis
- of the ARO 04-01 Def-RCT cohort was approved by the Ethical Committee of the Charité -
- 120 Universitätsmedizin Berlin (Berlin, Germany) in 2010 (EA2/086/10). Biomarker analysis of
- the DKTKRO Def-RCT was approved by the Ethical Committee of the Technical University
- of Dresden (Dresden, Germany) in 2014 (EK200112014).

2.2. Patient selection

- Within a European cooperative research project named SuPerTreat (research grant nr.
- ERAPERMED2019-281, further details in Funding), we first identified and constructed a

- multicenter dataset, which consisted primarily of data collected in previous research 127
- projects^{28–36} (NCT02832102, NCT03017573, NCT02059668) at the Fondazione IRCCS 128
- Istituto Nazionale dei Tumori (Milan, Italy), Institut Curie (Paris, France) and Charité -129
- Universitätsmedizin Berlin (Berlin, Germany) (Table S1 in supplementary information). We 130
- additionally included two public datasets (TCGA^{37,38} and GSE41613³⁹) that adhered to 131
- MIAME⁴⁰ and MINSEQE⁴¹ standards. 132
- The selected studies complied with the following **inclusion criteria**: 134
 - 1. Diagnosis of head and neck squamous cell carcinoma (HNSCC)
- 2. Planned treatment with curative intent 137
 - 3. Tumor specimens (formalin-fixed paraffin-embedded, FFPE) of HNSCC sampled prior to treatment, already assessed for gene expression analysis
 - 4. Stage I, II, III, IVA or IVB according to the tumor-node-metastasis (TNM) cancer staging system 7th edition⁴²
 - 5. One of the following tumor sites: oral cavity, oropharynx, hypopharynx, larynx
- 143 6. Age \geq 18 years

135

136

138

139

140

141

142

146

147

148

149

150 151

152

153

154

155

156

157

158 159 160

161

162

163

164

165

166 167

168

169

170

171

172 173

174

- A total of N = 1589 patients were screened from these studies. From these, patients were 144 excluded based on the following general exclusion criteria: 145
 - 1. Gene expression data not available
 - 2. Distant metastasis at diagnosis or missing information about stage
 - 3. Recurrent/metastatic disease at the time of study entry
 - 4. Missing information about survival timing or survival status
 - Additional exclusion criteria were applied when testing gene signatures related to sensitivity to systemic treatment:
 - 5. Early disease stage excluded when testing signatures pancancer-cisplatin and Cl3hypoxia. This specification is due to the fact that most early disease stage HNSCC patients are not treated with systemic treatment
 - 6. Missing treatment information about systemic treatment agent when testing signatures pancancer-cisplatin and Cl3-hypoxia

A total of 1097 patients were eligible for inclusion in this study, with the number reduced for gene signatures related to sensitivity to systemic treatment (Figure 1, Table S1). In models testing the signatures 172-GS, 3 clusters HPV and RSI, all 1097 patients were eligible for analyzing OS (Figure 1) and 907 patients were eligible for DFS (Figure S1). In models testing sensitivity to systemic treatment signatures (pancancer-cisplatin and Cl3-hypoxia), 750 patients were eligible for analyses of OS (Figure S2) and 700 patients were eligible for analyses of DFS (Figure S3).

None of the patients that were eligible for testing the signatures 172-GS, RSI, pancancercisplatin or Cl3-hypoxia were previously included in the development of these signatures. For the 3 clusters HPV GS, most of the eligible HPV-positive patients (N = 152, 14% of all eligible patients) were already part of a previous external validation of the signature 19, but in this study we additionally tested the GS in HPV-negative patients and adjusted for more covariates.

2.3. Endpoints, clinical variables and data harmonization

175

176

177

178

179 180

181

182

183

184 185

186

187

188

189

190

191

192

193

194

195

196

197

198 199

200

201

202 203

204

205

206

207

208

209

210

211

212

213 214

215

216

217 218

219

220

221

222

223

OS, defined as survival time from diagnosis until death of any cause or censoring, was recorded in all studies. DFS, defined as time from diagnosis until cancer recurrence or death of any cause, whichever occurred first, or censoring, was recorded in all but two studies (Table S1). Patients were followed for up to 20 years in the period 1989-2017. Co-primary endpoints were 2-year OS and 2-year DFS.

GSs were considered prognostic if they were associated with general disease prognosis independently of treatments. We defined a GS as predictive if the prognostic capability was limited to a population receiving a specific treatment.

Data harmonization of clinical variables was performed following head and neck ontology (HeNeCOn⁴³) and quality rules defined in BD2Decide study²⁸ (extended in the context of the SuPerTreat project), to achieve comparable measurements across studies (see Table 1 and Tables S2 and S3 for full list of clinical covariates). Tumor staging at diagnosis was performed according to the 7th edition of the AJCC/UICC staging system⁴². The staging variable was then classified in two main groups based on disease extension: early disease (stage I-II) vs. loco-regionally advanced disease (stage III-IVa/b). Human papillomavirus (HPV) infection is a known risk factor for oropharyngeal cancer⁴ and HPV-status was recorded for tumor tissues of all patients with oropharyngeal cancer, using either HPV DNA/RNA tests (with DNA PCR or ISH with or without E6/E7 mRNA confirmation, as per local guidelines) or through p16ink4a immunostaining. Non-oropharyngeal HNSCCs (including oral cavity cancers⁴⁴) were considered HPV-negative in analyses. Systemic treatments were coded in two ways: 1) platinum-based (if carboplatin and/or cisplatin were part of the agents a patient received) or non-platinum based (primarily cetuximab or paclitaxel); and 2) cetuximab-based (if cetuximab was part of the agents a patient received) or non-cetuximab based. Patients not receiving systemic treatments were in both cases coded as such.

Treatments (surgery, radiotherapy and systemic therapy) performed with curative intent were recorded as received or not received. This is potentially problematic since Cox regression survival models assume that covariates are measured at baseline (diagnosis) or require information about the timing of treatment. The use of the received treatment as a proxy for intended treatment (a baseline covariate) may result in immortal time bias⁴⁵. We performed extensive sensitivity analyses to evaluate if our results were sensitive to using received treatment as a covariate (Appendix 1). First, we considered the degree of mortality observed during the period prior to when treatments were initiated. Second, we used an external dataset (Head and Neck 5000^{46,47}) with similar patient characteristics as SuPerTreat and compared treatment coefficients from Cox models with either intended treatment or received treatment as covariates. Third, we compared treatment coefficients from Cox models with received treatment with models where treatment was considered time-dependent (in a subset of patients where the timing of surgery was known). Fourth, we used a landmark analysis 48,49 and compared treatment coefficients from a Cox model with received treatment with a landmark model where patients without an event or censoring prior to a landmark time point (corresponding with a time at which all patients started treatment) were followed from the landmark time. Lastly, we used quantitative bias analyses⁵⁰ to compare estimates of received treatments with bias-adjusted estimates of treatments. Based on these sensitivity analyses (Results section 3.3.1), we inferred that our models are robust to violations of the assumptions of the Cox regression models, and therefore used received treatment as a

covariate in our survival models. Although gene signatures are tested in interaction with 224 treatments, the tumor tissue used to obtain gene signature scores were sampled at diagnosis 225

(prior to treatment). 226

227

228

229

230

231

232

233

234

235

236

237

238

239

240 241

242

243

244

245

246 247

248

249 250

251

252

253

254

255

256

257

258

259

260

261

262 263

264 265

266

267

268

269

270

2.4. Bioinformatics analysis

Gene expression data was profiled on different platforms depending on the study. Three studies (study IDs: BD2 INT MI, BD2 UDUS, GSE41613) were profiled on Affymetrix microarrays (platforms GPL23126 and GPL570), one study (GECO110) was profiled on Illumina microarray (platform GPL14951), and two studies (SCANDARE, TCGA) were profiled using Illumina RNA-seq. Within studies, Affymetrix data were quantile-normalized using robust multi-array average (RMA). Illumina microarray data were quantile-normalized. For RNA-seq data, within studies, we first removed very lowly expressed genes, where genes were removed if all samples had < 0.25 counts per million (cpm), corresponding to max 5 reads in the smallest sample and max 22 reads in the largest sample. RNA-seq data were then quantile-normalized using the limma R package⁵¹ (function: voom). We used WGCNA package⁵² (function collapseRows and "maxRowVariance" method) to select the most variable probe in cases when multiple probes mapped to the same EntrezID. Probes and ensemble IDs that mapped to multiple EntrezID were removed. All gene expression data were log2-transformed after the abovementioned normalization. Genes that were missing for all patients in a study were removed when combining datasets. ComBat^{53,54} was used to remove batch effects introduced by systemic non-biological technical errors from combining data from multiple studies with different platforms. The largest proprietary study (ID: BD2 INT MI) was used as reference in ComBat, parametric adjustment was performed, and since there is variability in patient characteristics between studies, we only adjusted for the mean to not remove biological variance between the studies. To avoid bias in downstream analyses⁵⁵, we only included the batches (studies) as covariates in ComBat.

We calculated 5 gene signature scores for each patient following descriptions given in the original publications (see Table S4 for detailed list of genes and weights per signature). The signatures 172-GS¹⁸, 3 clusters HPV^{19,20}, pancancer-cisplatin²³, and Cl3-hypoxia²⁴ were calculated as weighed sums using the equation: Gene signature score = $\sum_{i=1}^{n} \beta_i \times Exp_i$, where β_i is the weight of the i-th gene (of n genes) and Exp_i is the gene expression of the i-th gene. The 172-GS signature was calculated using the hacksig package⁵⁶. The radiosensitivity index (RSI) signature is based on the expression of 10 specific genes. RSI was calculated as a weighed ranked sum using the equation: $RSI = \sum_{i=1}^{10} \beta_i \times Ranked Exp_i$, where β_i is the weight of the i-th gene and Ranked Exp_i is the ranked gene expression of the i-th gene. For each patient the 10 genes were ranked in ascending order using patient-specific expression data, where the gene with the lowest expression is assigned a value of 1, and the gene with the highest expression is assigned a value of 10.

Each gene signature was mean-centered and scaled by the standard deviation (SD) within its respective dataset to make the scores easier to interpret (mean = 0, SD = 1, see Appendix 2 for means and SD on original scale). In our OS dataset, 76% of the 172-GS signature genes were present, 46% of the 3 clusters HPV signature genes were present, all RSI genes were present, 92% of the pancancer-cisplatin genes were present, and 94% of the Cl3-hypoxia genes were present. For our DFS dataset, the presence of genes was 80% for the 172-GS signature, 57% for the 3 clusters HPV signature, all RSI genes present, 92% for pancancer-

- cisplatin and 94% for Cl3-hypoxia genes (see Appendix 2 for a list of missing genes per gene 271
- signature). Any missing genes were missing for all individuals, making regression-based 272
- imputation not a viable option. Instead, all missing genes were imputed as having zero 273
- expression. Note that the scaled signature values do not change if we instead were to impute 274
- with another constant (e.g., imputing the overall mean expression). 275

2.5. Statistical analyses

276

277

279

280

287

288

308

All statistical analyses were performed in R Statistical Software⁵⁷ (v4.1.3). 278

2.5.1. Handling of missing clinical covariates

- There were missing data in several categorical variables: smoking status, tumor stage and 281
- received treatments (i.e., surgery, systemic therapy and radiotherapy). The missingness was 282
- largely structural, resulting from some variables not being measured in some of the studies, 283
- and therefore regression-based imputation of missing data was not a viable option⁵⁸. Instead. 284
- we used a missing indicator where missing values were coded as belonging to a "missing" 285
- category (see Table 1 for amounts of missingness). 286

2.5.2. Clinical base models

- Clinical base models, i.e., those not including the gene expression data, were built as 289
- benchmark models for models which included gene signatures as covariates. Four Cox 290
- 291 proportional hazard models were fit with either 2-year OS or 2-year DFS as endpoints. Two
- models were fit with the same data used to test signatures not related to sensitivity to 292
- systemic treatment (172-GS, 3 clusters HPV and RSI) and two models were fit with the same 293
- data used to test signatures related to sensitivity to platinum-based or cetuximab-based 294
- treatments (pancancer-cisplatin and Cl3-hypoxia, respectively). In all models, age, sex, 295
- 296 tumor region and HPV-status, smoking status, undergone surgery (yes/no), received
- radiotherapy (yes/no), and study ID were used as covariates. In models testing signatures not 297
- 298 related to systemic treatment, disease extension (early stage, locoregionally advanced) and
- 299 received systemic therapy (yes/no) were also used as covariates. In models testing signatures
- 300 related to systemic treatment, TNM stage and a variable for systemic treatment (platinum-
- based version when testing pancancer-cisplatin; cetuximab-based version when testing Cl3-301
- hypoxia) were included as covariates. The concordance index (Harrell's C-index⁵⁹) was 302
- 303 calculated for each model to compare their discriminatory ability with the ability of models
- that included gene signatures (but see Hartman et al.⁶⁰ for limitations on interpreting the C-304
- index). Additionally, we calculated each models measure of explained variation (R²) as 305
- defined by Royston⁶¹ and building on previous work^{62,63}. This measure is similar to R² of 306
- linear models but was made for models analyzing censored survival data⁶¹. 307

2.5.3. Gene signature validation models

- 309 To validate prognostic gene signatures (172-GS and 3 clusters HPV), we fit Cox proportional
- hazard models where we tested if the gene signature was associated with survival endpoints 310
- while adjusting for other covariates. For each GS, we used the same endpoints and covariates 311

perpetuity.

It is made available under a CC-BY-NC 4.0 International license .

as in the clinical base models, but also tested for an interaction between HPV-status and the GS. This allowed us to test if the same association between survival and GSs was found in both HPV-positive and in HPV-negative patients.

To validate predictive gene signatures (*RSI*, *pancancer-cisplatin* and *Cl3-hypoxia*), we fit Cox proportional hazard models where we tested if gene signatures were associated with survival endpoints and if there was evidence that gene signatures modified the effect of the treatments (i.e., testing for an interaction between gene signatures and treatments). Finding a significant interaction where a GS is associated with survival in a specific treatment but not in others would imply that the signature is predictive. For validating each GS, we used the same covariates as in the clinical base models, but also included relevant interactions between GS and treatments. An interaction between radiotherapy and *RSI* was included when validating *RSI*. For validation of the *pancancer-cisplatin* signature, we included an interaction between the *pancancer-cisplatin* signature and systemic treatment. Similarly for validation of *Cl3-hypoxia*, we included an interaction between the *Cl3-hypoxia* signature and systemic treatment (see Appendix 3 for formulas for each GS model).

To test the proportional hazard assumption of our Cox models, we performed sensitivity analyses where we fit equivalent models as described above, using 5-year survival (both for OS and DFS) as the endpoint instead of 2-year survival. We additionally estimated the median follow-up time using the reverse Kaplan-Meier method⁶⁴.

3. Results

312

313

314315

316

317

318

319

320

321

322

323 324

325

326

327328

329

330 331

332333

334

335

348

3.1. Cohort characteristics

The largest dataset used for overall survival analyses, representing the full SuPerTreat cohort, 336 contained patients from 6 studies, where 67% of patients were from the two largest studies 337 (Table 1). The majority of patients were men (72%) and the cohort had a median age at 338 diagnosis of 61 years (SD = 12). Most patients had loco-regionally advanced disease (85%) 339 and underwent surgery (78%) and/or radiotherapy treatment (69%), with 42% of patients 340 341 receiving systemic treatment. There was heterogeneity in tumor regions, and the most frequent primary site was oral cavity (55%) (Table 1). Similar cohort characteristics were 342 observed in the dataset used for disease-free survival (Table 1), and in subsets of patients that 343 344 were used to test the effect of other GSs on survival endpoints (Tables S2, S3). Among patients who received systemic treatment with information available about the therapeutic 345 agent, 87.6% received platinum-based and 8.5% received cetuximab-based therapies (Table 346 S3). 347

3.2. Gene signatures

3.2.1. Prognostic signature: 172-GS

- 350 The 172-GS signature was significantly associated with 2-year OS in HPV-negative patients,
- 351 where increasing the signature score by 1 (representing an increase of 1 standard deviation)
- 352 resulted in 41% higher hazard (HR = 1.41 [CI: 1.25, 1.59], Table 2, Figure 2). No evidence of
- an interaction between the signature score and HPV-status was found (p = 0.621), indicating
- that the association between survival and the GS was similar in HPV-positive patients (HR =
- 1.87 [CI: 0.61, 5.78], Table 2). However, the score was not significantly associated with OS

in HPV-positive patients when testing the marginal effect of the signature conditioned on being HPV-positive (Table 2). When fixing the signature score at zero (representing the mean score), HPV-negative patients had a 4.27-fold higher hazard than HPV-positive patients (Table 2). The models C-index was 0.71 (SE = 0.02) and R^2 = 0.29. The C-index of the corresponding clinical base model (i.e. not including the GS as a covariate) was 0.69 (SE = 0.02) and $R^2 = 0.23$.

Similar effect sizes and significance levels were found for 2-year DFS, with a significant association between the signature score and survival in HPV-negative patients (HR = 1.36 [CI: 1.17, 1.59], Table 2). There was no evidence of an interaction between the signature score and HPV-status (p = 0.651), and the score was not significantly associated with DFS in HPV-positive patients when conditioned on being HPV-positive (Table 2). The models Cindex was 0.67 (SE = 0.02) and $R^2 = 0.22$. The corresponding clinical base model had a Cindex of 0.66 (SE = 0.02) and R^2 = 0.18. See Table S5 for details about other covariates included in the 172-GS models.

3.2.2. Prognostic signature: 3 clusters HPV

356

357

358

359

360

361 362

363

364

365

366

367

368

369

370 371

372

382

383

384

385

386

387

388

389 390

391

401

- There was a significant association between the 3 clusters HPV signature and 2-year OS in 373 HPV-positive patients, where increasing the signature score resulted in a lower hazard (HR = 374 375 0.41 [CI: 0.24, 0.71], Table 2, Figure 3). There was evidence of an interaction between the signature score and HPV-status (p = 0.007), indicating that the effect of the GS was different 376 in HPV-negative patients (HR = 0.89 [CI: 0.77, 1.02], Table 2). Moreover, the score was not 377 significantly associated with OS in HPV-negative patients (Table 2). These patients had a 378 4.17-fold higher hazard than HPV-positive patients when fixing the signature score at zero 379 (Table 2). The model had a $R^2 = 0.25$ and C-index = 0.69 (SE = 0.02). The C-index of the 380 corresponding clinical base model was 0.69 (SE = 0.02) and $R^2 = 0.23$. 381
 - We found similar effect sizes and significance levels for 2-year DFS, with a significant association between the GS and survival in HPV-positive patients (HR = 0.51 [CI: 0.33, 0.77], Table 2). Evidence of an interaction between the signature score and HPV-status was also found (p = 0.001), and the score was not significantly associated with DFS in HPVnegative patients (Table 2). The models C-index was 0.67 (SE = 0.02) and $R^2 = 0.20$. The Cindex of the corresponding clinical base model was 0.66 (SE = 0.02) and $R^2 = 0.18$. See Table S6 for details about other covariates included in the 3 clusters HPV models.

3.2.3. Predictive signature: radiosensitivity index (RSI)

The RSI was significantly associated with 2-year OS in patients receiving radiotherapy, 392 where a higher hazard was found when increasing the signature score (HR = 1.25 [CI: 1.08, 393 1.44], Table 2, Figure 4). We found no evidence of an interaction between RSI and 394 radiotherapy (p = 0.672), suggesting that the association between survival and RSI was the 395 same, although not significantly associated, in patients that did not receive radiotherapy (HR 396 397 = 1.17 [0.90, 1.52], Table 2, Figure 4). When RSI was set to zero, there was no significant association between survival and having received radiotherapy (Table 2). The models C-398 index was 0.70 (SE = 0.02) and $R^2 = 0.25$. The corresponding clinical base model had a C-399 index of 0.69 (SE = 0.02) and $R^2 = 0.23$. 400

- In contrast to OS, there was no significant association between 2-year DFS and RSI (Table 2). 402
- There was also no evidence of an interaction between RSI and having received radiotherapy 403
- (p = 0.601). The models C-index was 0.66 (SE = 0.02) and $R^2 = 0.18$. The corresponding 404
- clinical base models C-index was 0.66 (SE = 0.02) and $R^2 = 0.18$. See Table S7 for details 405
- about other covariates included in the RSI models. 406

3.2.4. Predictive signature: Pancancer-cisplatin

- There was a significant association between the *pancancer-cisplatin* signature and 2-year OS 409
- in patients receiving platinum-based chemotherapy, where a higher hazard was observed 410
- when increasing the signature (HR = 1.29 [CI: 1.04, 1.59], Table 2, Figure 5). When 411
- platinum-based chemotherapy was the reference, there was no evidence of interactions 412
- between the signature and systemic treatment (p = 0.200 when compared to non-platinum 413
- based, p = 0.908 when compared to no systemic therapy), suggesting that the association 414
- 415 between the signature and overall survival may be similar in these groups. However, there
- was no significant association between survival and the signature score when conditioning on 416
- receiving non-platinum based systemic therapy or when not receiving systemic treatment 417
- (Table 2, Figure 5). There was also no significant association between survival and systemic 418
- treatment when the signature score was set to zero (Table 2). The models $R^2 = 0.32$ and C-419
- index was 0.72 (SE = 0.02). The corresponding clinical base model had a C-index of 0.71420
- (SE = 0.02) and $R^2 = 0.30$. 421

407

408

422

430

431

447

- 423 In contrast to OS, we found no significant association between 2-year DFS and the
- 424 pancancer-cisplatin signature (Table 2). There was also no evidence of interactions between
- the score and systemic treatment when platinum-based chemotherapy was the reference (p = 425
- 0.258 when compared to non-platinum based, p = 0.571 when compared to no systemic 426
- treatment). The models C-index was 0.70 (SE = 0.02) and $R^2 = 0.28$. The C-index of the 427
- corresponding clinical base model was 0.70 (SE = 0.02) and $R^2 = 0.26$. See Table S8 for 428
- 429 details about other covariates included in the pancancer-cisplatin models.

3.2.5. Predictive and prognostic signature: Cl3-hypoxia

- The Cl3-hypoxia signature was significantly associated with 2-year OS in patients receiving 432
- non-cetuximab-based systemic treatments, where increasing the signature score resulted in a 433
- lower hazard (HR = 0.69 [CI: 0.54, 0.87], Table 2, Figure 6). A similar, but non-significant, 434
- association between OS and the GS was found for cetuximab-treated patients (HR = 0.67 [CI: 435
- 436 0.39, 1.14], Table 2, Figure 6). In contrast, an opposite association was found between OS
- and the signature in patients who did not receive systemic treatments, where higher signature 437
- scores were associated with higher hazards (HR = 1.70 [CI: 1.12, 2.58], Table 2, Figure 6). 438
- There was evidence of interactions between the signature and systemic treatment when using 439
- 440 no systemic treatment as the baseline (comparison with cetuximab group: p = 0.006;
- 441 comparison with non-cetuximab: p < 0.001), but no evidence of an interaction when
- comparing cetuximab-treated patients with patients receiving other types of systemic 442
- 443 treatment (p = 0.919). When the GS score was set to zero, there was no significant
- association between survival and systemic treatment (Table 2). The models C-index was 0.73 444
- (SE = 0.02) and $R^2 = 0.34$. The C-index of the corresponding clinical base model (i.e. not 445
- including the GS as a covariate) was 0.71 (SE = 0.02) and $R^2 = 0.29$. 446

- Similar effect sizes and significance levels were found when analyzing 2-year DFS (Table 2). 448
- Increasing the signature score was associated with a reduced hazard in patients receiving 449
- systemic treatment, while being significantly associated with an increased hazard in patients 450
- not receiving systemic treatments (Table 2). There was evidence of interactions between the 451
- signature and systemic treatment when no systemic treatment was the baseline (comparison 452
- with cetuximab group: p = 0.006; comparison with non-cetuximab: p < 0.001), but no 453
- evidence of an interaction when comparing patients receiving cetuximab with patients 454
- receiving non-cetuximab therapies (p = 0.943). The models $R^2 = 0.32$ and C-index = 0.71 (SE 455
- = 0.02). The C-index of the corresponding clinical base model was 0.70 (SE = 0.02) and R^2 = 456
- 457 0.27. See Table S9 for details about other covariates included in the Cl3-hypoxia GS.

3.3. Sensitivity analyses

3.3.1. Coding of treatment

458

459

460

461

462 463

464

465

466

467

468

469

470

471

472

473

474

475 476

477

486

487

We performed sensitivity analyses to evaluate the effect of using the received treatment as a proxy of intended treatment (Appendix 1). Results of these analyses are summarized below:

- i) All treated patients started treatment within 6 months after diagnosis, with most starting treatment within 3-4 months. In the first 6 months after diagnosis, the mortality was approximately 3%.
- We obtained overlapping and similar treatment coefficients when comparing ii) intended and received treatment in an external dataset with similar patients' characteristics.
- We obtained overlapping and similar treatment coefficients when comparing iii) received treatment with time-dependent treatment in a subset of patients where the timing of surgery was known.
- A landmark analysis showed overlapping and similar treatment coefficients as iv) when using received treatment.
- Quantitative bias analyses showed bias-adjusted estimates of treatment effects that v) overlap with estimates obtained when using received treatment.

3.3.2. 5-year endpoints

- Effect sizes and significance levels from models with 5-year OS and 5-year DFS were very 478
- 479 similar to the 2-year survival models (see Figures S4-S13 for forest plots and Tables S5-S9
- for detailed results). The main difference was in the model of 5-year OS and the Cl3-hypoxia 480
- signature, where there was no longer evidence of an association between the score and 481
- survival in patients not receiving systemic treatments (HR = 1.43 [CI: 0.96, 2.13], p = 0.076). 482
- Moreover, there was no longer evidence of an interaction between the score and systemic 483
- treatment when comparing patients untreated with systemic agents with patients receiving 484
- 485 cetuximab (p = 0.068). The median follow-up time was 1325 days (approx. 3.63 years).

4. Discussion

In this study, we externally validated five gene signatures using one of the world's largest 488 489

collections of HNSCC patients with available gene expression, harmonizing and combining

high quality clinical data from different studies. The development of this wide European dataset has shown that the integration of multisource clinical and biological databases is feasible. This successful integration is unprecedented and amplifies the knowledge about the complexity and the heterogeneity of HNSCCs, contributing to their qualification and quantification. The external validation ensures the robustness of the GSs and their potential generalizability. In addition, tumor heterogeneity and complexity coupled with the variety of treatment options imposes a biology-driven personalized approach in the curative setting of HNSCC patients. Unlike more frequent tumors (e.g., breast cancer, non-small cell lung cancer, or colorectal cancer), GSs have not been included yet either in clinical decision making, or in clinical trial eligibility and stratification of HNSCC patients.

490

491

492

493

494

495

496

497

498

499 500

501 502

503

504

505 506

507

508 509

510

511

512

513

514 515

516

517

518

519 520

521

522

523

524 525

526

527

528

529 530

531

532

533 534

535

536 537

538

539

Except for the model testing associations between RSI and disease-free survival, all models including gene signatures outperformed their corresponding clinical omics-free base models, as indicated by C-index and/or R². Our results confirmed two potentially prognostic signatures (172-GS and 3 clusters HPV) and validated one potentially prognostic/predictive signature (Cl3-hypoxia) for cetuximab- and chemosensitivity. However, the results for two potentially predictive signatures (RSI and pancancer-cisplatin) were less conclusive, despite showing associations with overall survival in patients receiving radiotherapy or platinumbased chemotherapy.

The signature 172- GS^{18} was validated as a prognostic indicator for both overall and diseasefree survival in patients with HPV-unrelated disease. A higher signature score is associated with a higher risk. The signature may also be prognostic in HPV-positive oropharyngeal cancer patients, as given by the lack of evidence of an interaction between the signature and HPV-status. This contrasts with previously published results¹⁹, possibly due to adjustments for covariates and uncertainties in estimates of the signature effect for HPV-positive patients.

The 3 clusters HPV signature²⁰ was validated as prognostic for both OS and DFS in HPVpositive oropharyngeal cancer patients, consistent with a previous validation study¹⁹. Additionally, there was no evidence of the signature being prognostic for HPV-negative patients, suggesting its relevance specifically to HPV-positive oropharyngeal cancer.

In our study, we found a link between the radiosensitivity index $(RSI)^{21}$ and overall survival in patients who underwent radiotherapy, consistent with other studies 18,19,22,65. However, we did not observe any interaction between RSI and radiotherapy. We also found a similar but not significant association between RSI and OS in patients who did not receive radiotherapy. This suggests that RSI may be more prognostic for survival than predictive of radiosensitivity. This surprising finding of a prognostic effect of RSI in non-irradiated patients may be because of the relatively low number of non-irradiated patients in our study. In contrast to other studies 22,66 , we did not find a connection between RSI and DFS.

To our knowledge this is the first external validation of the *pancancer-cisplatin* signature²³ in head and neck cancer patients. We found a negative association between the signature score and overall survival (OS) in patients receiving platinum-based chemotherapy. Given that higher GS scores were linked to higher cisplatin-sensitivity in the original publication²³, our finding is in the opposite direction of what is expected. Additionally, we did not find evidence of an interaction between systemic treatment and the signature. Due to an imbalance in the number of patients with each type of systemic treatment, we could not draw definitive conclusions about the potential prognostic or predictive effects of the signature. Lastly, we found no associations between disease-free survival (DFS) and the pancancer-cisplatin

signature, suggesting that its predictive power may vary with clinical outcomes and not be universal for all cancers.

540

541 542

543

544

545

546

547

548 549

550

551

552

553

554

555 556 557

558 559

560

561

562

563

564 565

566

567

568

569

570

571

572 573

574 575

576

577 578

579

580 581

582 583

584

585

586 587

588

589

In general, a GS is prognostic if it is able to forecast patient survival independently of the received treatment. At the same time, if a prognostic GS is tested on a subset of patients receiving curative therapies including a specific approach, then the prognostic performance necessarily implies a certain predictive capability. In this scenario, the Cl3-hypoxia²⁴ signature score was positively associated with both OS and DFS in patients receiving systemic treatment but negatively associated with survival in subjects not receiving systemic agents, suggesting the signature is predictive of sensitivity to systemic therapy. A similar positive association with survival endpoints was found in both cetuximab-treated patients and in patients with chemotherapy, which did not include anti-EGFR agents. The association between signature and survival is consistent with previous findings in HPV-positive oropharyngeal cancer¹⁹ and in oral premalignant lesions²⁵. Previous studies have suggested that the signature is related to cetuximab-sensitivity^{26,27}, but our results indicate that it is predictive of sensitivity to systemic treatment in general.

This study offers various opportunities for further improvement and refinement. Firstly, we used the received treatment as a proxy for intended treatment. While this breaks an assumption of the Cox regression model, we performed extensive sensitivity analyses that suggest the models are robust to this violation. Secondly, 3-7% of patients (depending on the model) were excluded for missing overall survival status or timing, and 6-19% were excluded for missing DFS. This complete case exclusion reduced the sample sizes. Still, because the missingness was primarily structural⁵⁸, where the survival endpoint was missing for all patients in a study, it is unlikely that it biased the results. Third, we used the missing indicator method for missing covariates (with missingness ranging from 3-30% depending on the covariate), which can lead to biased results in non-randomized studies⁶⁷, but is unlikely to result in bias unless the covariate is a strong confounder or missing in extreme proportion (>50% missing)⁶⁸. Moreover, like the missingness in endpoints, the missingness in covariates was primarily structural, and alternative regression-based imputation methods were therefore not a viable option. Lastly, the imbalance in the number of patients with different treatments (e.g., only 35 patients received cetuximab) made it difficult to precisely estimate interactions and effects of gene signatures in small groups and made conclusions less clear.

We externally validated five gene signatures using a large integrated dataset of HNSCC patients. Our results validated two prognostic signatures, 172-GS and 3 clusters HPV signature, in HPV-negative patients and HPV-positive patients, respectively. We also validated that the potentially predictive signatures RSI and pancancer-cisplatin were prognostic of survival in patients with radiotherapy and platinum-based chemotherapy, respectively, but could not conclude if these signatures are also predictive of radiosensitivity or platinum-chemosensitivity. Lastly, we validated the Cl3-hypoxia signature as predictive of sensitivity to systemic treatment, making this signature a good candidate for use in personalized treatment decisions.

Many clinical studies aimed at intensifying^{69–71} or de-escalating^{72–74} standard treatments have failed in head and neck oncology. A possible drawback could be the lack of an appropriate patient selection, which may have hampered the opportunity to detect a signal of clinical benefit with a given therapeutic approach. The significant biological differences in the current study demonstrate the high heterogeneity of HNSCCs. Therefore, future clinical trials should pursue a better patient selection that includes a broader use of GS and incorporates

perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

- them as inclusion criteria or stratification factors. In this scenario, the results of our external
- validation in one of the widest HNSCC datasets may be considered a historical benchmark
- for the design of future studies.

593

594

599

603

604

618

619

5. Data availability

- 595 The SuPerTreat dataset is hosted by the Services for Sensitive Data (TSD) at the University
- of Oslo. Anonymized data containing only the survival endpoints and gene signature scores
- 597 will be uploaded to Zenodo prior to publication. Access to the original data may be granted
- 598 by the data owners upon application.

6. Code availability

- The underlying code (R scripts) used to analyse and validate gene signatures is available on
- 601 GitHub and can be accessed via this link
- 602 https://github.com/erlendfossen/SuPerTreat GS validation.

7. Acknowledgements

- This work is part of the research project "Supporting Personalized Treatment Decisions in
- Head and Neck Cancer through Big Data (SuPerTreat)" funded within ERA PerMed
- JTC2019 Joint transnational call for proposals (2019) for "Personalised medicine:
- 608 multidisciplinary research Toward implementation", research grant nr. ERAPERMED2019-
- 609 281 and supported by FRRB (Fondazione Regionale per la Ricerca Biomedica), BMBF
- 610 (Bundesministerium für Bildung und Forschung), RCN (Norges forskningsråd), ANR
- 611 (Agence nationale de la recherche) and GSRT (General Secretariat for Research and
- Technology). MM-S received funding from the European Union's Horizon 2020
- Research and Innovation program under the Marie Skłodowska-Curie Actions Grant,
- agreement No. 80113 (Scientia fellowship). BD2Decide received funding from the European
- 615 Union Horizon 2020 Framework Programme, Grant/Award Number: 689715. We thank the
- researchers, clinicians and other staff that designed and conducted the studies that this work
- builds on. We also thank the head and neck cancer patients that took part in the studies.

8. Author contributions

- 620 Conceptualization: E.I.F.F., M.M.S., M.L., A.F., I.T., C.L.T., L.L, L.D.C, S.C.; Data curation:
- 621 E.I.F.F., M.M.S., L.L.P, E.E.P, L.H, L.D.C, S.C.; Formal analysis: E.I.F.F., M.M.S., M.L.,
- A.F., L.D.C, S.C.; Funding acquisition: A.F., E.H., M.F.C.U, G.F., I.T., L.L.; Investigation:
- 623 I.T., V.S., K.S., C.L.T., M.K., S.T., M.P., L.L, L.D.C, S.C.; Methodology: E.I.F.F., M.M.S.,
- M.L., A.F., L.L, L.D.C, S.C.; Resources: A.F., L.L.; Software: E.I.F.F., M.M.S.; Supervision:
- M.L., A.F., M.F.C.U., G.F.; Visualization: E.I.F.F.; Writing-original draft: E.I.F.F.; Writing-

perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

review & editing: All authors. All authors approved the submission of this manuscript. L.D.C. 626 627

and S.C. contributed equally to this work as co-last authors.

Competing interests

628

629

630

631 632

633

634

635

636

637

638

639

640

641

M.L. reports receiving a speaker fee from MSD unrelated to the content of this work. L.L. declares the following conflicts of interest, all unrelated to the content of this work: research funds donated directly to the institute for clinical trials from AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, Hoffmann-La Roche Ltd, IRX Therapeutics, Medpace, Merck-Serono, MSD, Novartis, Pfizer, Roche, and Buran; occasional fees for participation as a speaker at conferences/congresses or as a scientific consultant for advisory boards from AstraZeneca, Bayer, MSD, Merck-Serono, AccMed, Neutron Therapeutics, Inc., and Alentis. S.C. declares occasional fees for participation as a speaker at conferences/congresses from AccMed; support for attending meetings and/or travel from AccMed, MultiMed Engineers srl, Care Insight sas, unrelated to the content of this work. All remaining authors declare no competing interests.

References

- 643 1. Barsouk, A., Aluru, J. S., Rawla, P., Saginala, K. & Barsouk, A. Epidemiology, Risk Factors, and
- 644 Prevention of Head and Neck Squamous Cell Carcinoma. Med. Sci. 11, 42 (2023).
- 2. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality 645
- 646 Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 71, 209–249 (2021).
- 647 Gormley, M., Creaney, G., Schache, A., Ingarfield, K. & Conway, D. I. Reviewing the epidemiology
- 648 of head and neck cancer: definitions, trends and risk factors. Br. Dent. J. 233, 780-786 (2022).
- Sabatini, M. E. & Chiocca, S. Human papillomavirus as a driver of head and neck cancers. Br. J. 649
- 650 Cancer 122, 306-314 (2020).
- 651 Leemans, C. R., Snijders, P. J. F. & Brakenhoff, R. H. The molecular landscape of head and neck
- 652 cancer. Nat. Rev. Cancer 18, 269-282 (2018).
- Mes, S. W., Leemans, C. R. & Brakenhoff, R. H. Applications of molecular diagnostics for 653
- 654 personalized treatment of head and neck cancer: state of the art. Expert Rev. Mol. Diagn. 16,
- 655 205-221 (2016).
- 656 7. Reid, P. et al. Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in
- 657 cancer stem cell heterogeneity, plasticity and treatment response. Radiother. Oncol. 135, 1-12
- 658 (2019).
- 8. Machiels, J.-P. et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and 659
- 660 hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and
- follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 31, 1462-1475 (2020). 661
- 662 Gatta, G. et al. Burden and centralised treatment in Europe of rare tumours: results of
- RARECAREnet—a population-based study. Lancet Oncol. 18, 1022–1039 (2017). 663
- 10. Ballman, K. V. Biomarker: Predictive or Prognostic? J. Clin. Oncol. 33, 3968–3971 (2015). 664
- 665 11. Al-Tashi, Q. et al. Machine Learning Models for the Identification of Prognostic and Predictive
- 666 Cancer Biomarkers: A Systematic Review. Int. J. Mol. Sci. 24, 7781 (2023).

- 667 12. Huo, M. et al. Tumor microenvironment characterization in head and neck cancer identifies
- prognostic and immunotherapeutically relevant gene signatures. Sci. Rep. 10, 11163 (2020). 668
- 669 13. Feng, B. & Hess, J. Immune-Related Mutational Landscape and Gene Signatures: Prognostic
- 670 Value and Therapeutic Impact for Head and Neck Cancer. Cancers 13, 1162 (2021).
- 671 14. Wang, J. et al. Six-gene signature for predicting survival in patients with head and neck
- 672 squamous cell carcinoma. Aging 12, 767-783 (2020).
- 673 15. Liu, B. et al. Prognostic Value of Eight-Gene Signature in Head and Neck Squamous Carcinoma.
- 674 Front. Oncol. 11, (2021).
- 16. Tonella, L., Giannoccaro, M., Alfieri, S., Canevari, S. & De Cecco, L. Gene Expression Signatures 675
- for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application? Curr. 676
- 677 Treat. Options Oncol. 18, 32 (2017).
- 678 17. Steckler, A. & McLeroy, K. R. The Importance of External Validity. Am. J. Public Health 98, 9-10
- 679 (2008).
- 18. De Cecco, L., Bossi, P., Locati, L., Canevari, S. & Licitra, L. Comprehensive gene expression meta-680
- 681 analysis of head and neck squamous cell carcinoma microarray data defines a robust survival
- predictor. Ann. Oncol. 25, 1628-1635 (2014). 682
- 19. Cavalieri, S. et al. Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in 683
- 684 Human Papillomavirus-Positive Oropharyngeal Carcinoma. JCO Precis. Oncol. 1666-1676 (2021)
- 685 doi:10.1200/PO.21.00094.
- 686 20. Locati et al. Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic
- 687 Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. Cancers 11, 1057
- 688 (2019).
- 21. Eschrich, S. A. et al. A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of 689
- Response and Prognosis After Chemoradiation. Int. J. Radiat. Oncol. 75, 489-496 (2009). 690
- 691 22. Torres-Roca, J. F., Grass, G. D., Scott, J. G. & Eschrich, S. A. Towards Data Driven RT Prescription:
- 692 Integrating Genomics into RT Clinical Practice. Semin. Radiat. Oncol. 33, 221-231 (2023).

- 693 23. Wells, J. D., Griffin, J. R. & Miller, T. W. Pan-Cancer Transcriptional Models Predicting
- 694 Chemosensitivity in Human Tumors. Cancer Inform. 20, 117693512110024 (2021).
- 24. De Cecco, L. et al. Head and neck cancer subtypes with biological and clinical relevance: Meta-695
- 696 analysis of gene-expression data. Oncotarget 6, 9627–9642 (2015).
- 697 25. Carenzo, A. et al. Gene Expression Clustering and Selected Head and Neck Cancer Gene
- 698 Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. Cells 9, 1828
- 699 (2020).
- 700 26. Bossi, P. et al. Functional Genomics Uncover the Biology behind the Responsiveness of Head and
- 701 Neck Squamous Cell Cancer Patients to Cetuximab. Clin. Cancer Res. 22, 3961-3970 (2016).
- 27. Lenoci, D. et al. Biological properties of hypoxia-related gene expression models/signatures on 702
- 703 clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity
- 704 trials. Oral Oncol. 126, 105756 (2022).
- 705 28. Cavalieri, S. et al. Development of a multiomics database for personalized prognostic forecasting
- 706 in head and neck cancer: The Big Data to Decide EU Project. Head Neck 43, 601–612 (2021).
- 707 29. Sablin, M.-P. et al. Identification of new candidate therapeutic target genes in head and neck
- squamous cell carcinomas. Oncotarget 7, 47418–47430 (2016). 708
- 709 30. Neuzillet, C. et al. Prognostic value of intratumoral Fusobacterium nucleatum and association
- 710 with immune-related gene expression in oral squamous cell carcinoma patients. Sci. Rep. 11,
- 711 7870 (2021).
- 31. Hoffmann, C. et al. MMP2 as an independent prognostic stratifier in oral cavity cancers. 712
- 713 Oncoimmunology 9, 1754094 (2020).
- 714 32. Leblanc, O. et al. Biomarkers of cetuximab resistance in patients with head and neck squamous
- cell carcinoma. Cancer Biol. Med. 17, 208-217 (2020). 715
- 33. Lecerf, C. et al. Immune gene expression in head and neck squamous cell carcinoma patients. 716
- 717 Eur. J. Cancer 121, 210-223 (2019).

- 718 34. Hoffmann, C. et al. PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in
- 719 cancer, allergy and autoimmunity. Nat. Commun. 13, 1983 (2022).
- 720 35. Moreira, A. et al. Prognostic value of tumor mutational burden in patients with oral cavity
- 721 squamous cell carcinoma treated with upfront surgery. ESMO Open 6, 100178 (2021).
- 722 36. Karabajakian, A. et al. Longitudinal assessment of PD-L1 expression and gene expression profiles
- 723 in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncol. 119, 105368
- 724 (2021).
- 725 37. The Cancer Genome Atlas (TCGA). https://www.cancer.gov/tcga.
- 726 38. Lawrence, M. S. et al. Comprehensive genomic characterization of head and neck squamous cell
- 727 carcinomas. Nature **517**, 576–582 (2015).
- 728 39. Lohavanichbutr, P. et al. A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and
- 729 External Validation. Clin. Cancer Res. 19, 1197–1203 (2013).
- 730 40. Brazma, A. et al. Minimum information about a microarray experiment (MIAME)—toward
- 731 standards for microarray data. Nat. Genet. 29, 365–371 (2001).
- 732 41. Brazma, A. et al. MINSEQE: Minimum Information about a high-throughput Nucleotide
- 733 SeQuencing Experiment - a proposal for standards in functional genomic data reporting. (2012)
- doi:10.5281/zenodo.5706412. 734
- 735 42. Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th Edition of the
- 736 AJCC Cancer Staging Manual and the Future of TNM. Ann. Surg. Oncol. 17, 1471–1474 (2010).
- 737 43. Hernández, L. et al. HeNeCOn: An ontology for integrative research in Head and Neck cancer.
- Int. J. Med. Inf. 181, 105284 (2024). 738
- 739 44. Nauta, I. H. et al. The unveiled reality of human papillomavirus as risk factor for oral cavity
- 740 squamous cell carcinoma. *Int. J. Cancer* **149**, 420–430 (2021).
- 45. Jones, M. & Fowler, R. Immortal time bias in observational studies of time-to-event outcomes. J. 741
- 742 Crit. Care 36, 195-199 (2016).

- 743 46. Ness, A. R. et al. Establishing a large prospective clinical cohort in people with head and neck
- 744 cancer as a biomedical resource: head and neck 5000. BMC Cancer 14, 973 (2014).
- 745 47. Ness, A. R. et al. Recruitment, response rates and characteristics of 5511 people enrolled in a
- prospective clinical cohort study: head and neck 5000. Clin. Otolaryngol. 41, 804–809 (2016). 746
- 747 48. Mi, X., Hammill, B. G., Curtis, L. H., Lai, E. C.-C. & Setoguchi, S. Use of the landmark method to
- 748 address immortal person-time bias in comparative effectiveness research: a simulation study.
- 749 Stat. Med. 35, 4824-4836 (2016).
- 750 49. Gleiss, A., Oberbauer, R. & Heinze, G. An unjustified benefit: immortal time bias in the analysis
- 751 of time-dependent events. Transpl. Int. 31, 125–130 (2018).
- 752 50. Lash, T. L., Fink, A. K. & Fox, M. P. Misclassification. in Applying Quantitative Bias Analysis to
- 753 Epidemiologic Data (eds. Lash, T. L., Fox, M. P. & Fink, A. K.) 79–108 (Springer, New York, NY,
- 754 2009). doi:10.1007/978-0-387-87959-8_6.
- 755 51. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and
- 756 microarray studies. Nucleic Acids Res. 43, e47 (2015).
- 757 52. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis.
- BMC Bioinformatics 9, 559 (2008). 758
- 53. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using 759
- 760 empirical Bayes methods. *Biostatistics* **8**, 118–127 (2007).
- 761 54. Zhang, Y., Jenkins, D. F., Manimaran, S. & Johnson, W. E. Alternative empirical Bayes models for
- 762 adjusting for batch effects in genomic studies. BMC Bioinformatics 19, 262 (2018).
- 763 55. Nygaard, V., Rødland, E. A. & Hovig, E. Methods that remove batch effects while retaining group
- 764 differences may lead to exaggerated confidence in downstream analyses. Biostatistics 17, 29–39
- 765 (2016).
- 56. Carenzo, A. et al. hacksig: a unified and tidy R framework to easily compute gene expression 766
- 767 signature scores. Bioinformatics 38, 2940–2942 (2022).

- 768 57. R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for
- 769 Statistical Computing, Vienna, Austria, 2022).
- 58. Mitra, R. et al. Learning from data with structured missingness. Nat. Mach. Intell. 5, 13-23 770
- 771 (2023).
- 772 59. Harrell, F. E., Jr, Califf, R. M., Pryor, D. B., Lee, K. L. & Rosati, R. A. Evaluating the Yield of Medical
- 773 Tests. JAMA 247, 2543-2546 (1982).
- 774 60. Hartman, N., Kim, S., He, K. & Kalbfleisch, J. D. Pitfalls of the concordance index for survival
- 775 outcomes. Stat. Med. 42, 2179-2190 (2023).
- 776 61. Royston, P. Explained Variation for Survival Models. Stata J. 6, 83-96 (2006).
- 777 62. O'Quigley, J., Xu, R. & Stare, J. Explained randomness in proportional hazards models. Stat. Med.
- 778 **24**, 479–489 (2005).
- 779 63. Nagelkerke, N. J. D. A note on a general definition of the coefficient of determination.
- 780 Biometrika 78, 691-692 (1991).
- 64. Shuster, J. J. Median follow-up in clinical trials. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 9, 191-781
- 782 192 (1991).
- 783 65. Dai, Y.-H. et al. Radiosensitivity index emerges as a potential biomarker for combined
- 784 radiotherapy and immunotherapy. Npj Genomic Med. 6, 40 (2021).
- 785 66. Torres-Roca, J. F. A molecular assay of tumor radiosensitivity: a roadmap towards biology-based
- 786 personalized radiation therapy. Pers. Med. 9, 547-557 (2012).
- 787 67. Groenwold, R. H. H. et al. Missing covariate data in clinical research: when and when not to use
- 788 the missing-indicator method for analysis. CMAJ 184, 1265–1269 (2012).
- 789 68. Song, M., Zhou, X., Pazaris, M. & Spiegelman, D. The Missing Covariate Indicator Method is
- 790 Nearly Valid Almost Always. Preprint at https://doi.org/10.48550/arXiv.2111.00138 (2021).
- 69. Merck. Merck Provides Update on Xevinapant Program in Locally Advanced Head and Neck 791
- 792 Cancer [Press release]. https://www.merckgroup.com/en/news/xevinapant-update.html (2024).

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

70. Lee, N. Y. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22, 450-462 (2021). 71. Machiels, J.-P. et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 25, 572-587 (2024). 72. Mehanna, H. et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomaviruspositive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. The Lancet 393, 51-60 (2019). 73. Gillison, M. L. et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. The Lancet 393, 40-50 (2019). 74. Tao, Y. et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann. Oncol. 34, 101-110 (2023).

Table 1. Cohort characteristics for head and neck cancer patients used to test the 172-GS and 3 clusters HPV signatures. The disease-free survival (DFS) dataset is a subset of the overall survival dataset, where patients without data on DFS are excluded.

813

814

815

	Overall survival dataset (N=1097)	Disease-free survival dataset (N=907)
172-GS score	-	
Mean (SD)	0.0 (1.0)	0.0 (1.0)
Median (Min, Max)	0.1 (-4.5, 3.6)	0.1 (-4.9, 3.5)
3 clusters HPV score		
Mean (SD)	0.0 (1.0)	0.0 (1.0)
Median (Min, Max)	0.0 (-2.8, 6.9)	0.0 (-2.9, 3.5)
Study ID		
BD2 INT MI	310 (28.3%)	310 (34.2%)
BD2 UDUS	127 (11.6%)	127 (14.0%)
GECO110	107 (9.8%)	107 (11.8%)
GSE41613	97 (8.8%)	0 (0%)
SCANDARE	32 (2.9%)	0 (0%)
TCGA	424 (38.7%)	363 (40.0%)
Clinical age at diagnosis	,	,
Mean (SD)	61.0 (11.9)	60.8 (11.7)
Median (Min, Max)	61.0 (19.0, 93.0)	61.0 (19.0, 93.0)
Clinical sex		(1010, 0010,
Male	794 (72.4%)	660 (72.8%)
Female	303 (27.6%)	247 (27.2%)
Disease extension at diagnosis	(2.16.5)	= (= = / .)
Early disease	161 (14.7%)	98 (10.8%)
Locoregionally advanced disease	936 (85.3%)	809 (89.2%)
Tumor region	000 (00.070)	000 (00.270)
Oropharynx	227 (20.7%)	218 (24.0%)
Hypopharynx	55 (5.0%)	52 (5.7%)
Larynx	165 (15.0%)	150 (16.5%)
Oral cavity	598 (54.5%)	451 (49.7%)
Missing	52 (4.7%)	36 (4.0%)
HPV status	02 (1.170)	00 (1.070)
Positive	156 (14.2%)	151 (16.6%)
Negative	941 (85.8%)	756 (83.4%)
Smoking	941 (00.070)	730 (03.470)
Never	230 (21.0%)	213 (23.5%)
Current or Former	653 (59.5%)	609 (67.1%)
Missing	214 (19.5%)	85 (9.4%)
Undergone cancer surgery	214 (19.576)	03 (9.470)
	107 (17 00/)	197 (20 60/)
No Yes	187 (17.0%)	187 (20.6%)
	854 (77.8%)	672 (74.1%) 48 (5.3%)
Missing	56 (5.1%)	40 (3.3%)
Radiotherapy treatment	209 (40 00/)	146 (16 10/)
No You	208 (19.0%)	146 (16.1%)
Yes	752 (68.6%)	633 (69.8%)
Missing	137 (12.5%)	128 (14.1%)
Systemic treatment	202 (27 59/)	222 (25 72)
No	302 (27.5%)	233 (25.7%)
Yes	461 (42.0%)	426 (47.0%)
Missing	334 (30.4%)	248 (27.3%)

Table 2. Hazard ratios (HR) of gene signatures and covariates that were tested in interaction with the signatures for head and neck cancer patients. Estimates are from models where 2year overall survival or 2-year disease-free survival was the endpoint and the effect of other clinical covariates were jointly estimated (see Tables S5, S6, S7, S8, S9 for detailed results).

Signature	Variable	Danamatan	Overall survival		Disease-free survival	
		Parameter	HR [95% CI]	P-value	HR [95% CI]	P-value
172-GS	HPV-status	HPV positive	Reference	-	Reference	-
		HPV negative	4.27 [2.03, 9.01]	< 0.001	4.43 [2.44, 8.02]	< 0.001
	Signature score	Score given HPV positive	1.87 [0.61, 5.78]	0.274	1.67 [0.69, 4.05]	0.254
		Score given HPV negative	1.41 [1.25, 1.59]	< 0.001	1.36 [1.17, 1.59]	< 0.001
3 clusters HPV	HPV-status	HPV positive	Reference	-	Reference	-
		HPV negative	4.17 [2.03, 8.57]	< 0.001	4.01 [2.26, 7.14]	< 0.001
	Signature score	Score given HPV positive	0.41 [0.24, 0.71]	0.001	0.51 [0.33, 0.77]	0.001
		Score given HPV negative	0.89 [0.77, 1.02]	0.084	1.06 [0.91, 1.23]	0.454
RSI	D 1: .1	No	Reference		Reference	
	Radiotherapy	Yes	0.81 [0.54, 1.21]	0.306	1.08 [0.82, 1.42]	0.601
	Signature score	Score given radiotherapy = no	1.17 [0.90, 1.52]	0.249	1.01 [0.79, 1.27]	0.929
		Score given radiotherapy = yes	1.25 [1.08, 1.44]	0.003	1.08 [0.82, 1.42]	0.306
Pancancer- cisplatin	~ .	Platinum based	Reference	-	Reference	-
	Systemic therapy	Non-platinum based	0.57 [0.28, 1.15]	0.114	0.94 [0.44, 2.01]	0.873
	шегару	No systemic treatment	1.24 [0.75, 2.04]	0.409	0.97 [0.63, 1.49]	0.882
	Signature score	Score given systemic therapy = platinum based	1.29 [1.04, 1.59]	0.020	1.23 [0.82, 1.84]	0.316
		Score given systemic therapy = non-platinum based	0.82 [0.42, 1.59]	0.552	2.00 [0.90, 4.45]	0.089
		Score given systemic therapy = no	1.37 [0.51, 3.69]	0.540	0.92 [0.37, 2.31]	0.862
Cl3- hypoxia	Systemic therapy	Cetuximab based	Reference		Reference	
		Non-cetuximab based	1.07 [0.49, 2.31]	0.869	0.71 [0.34, 1.48]	0.363
		No systemic treatment	1.22 [0.51, 2.91]	0.657	0.69 [0.31, 1.54]	0.364
	Signature score	Score given systemic therapy = cetuximab based	0.67 [0.39, 1.14]	0.137	0.61 [0.33, 1.13]	0.114
		Score given systemic therapy = non-cetuximab based	0.69 [0.54, 0.87]	0.002	0.59 [0.44, 0.80]	0.001
		Score given systemic therapy = no	1.70 [1.12, 2.58]	0.013	1.71 [1.14, 2.56]	0.010

818

819




Figure 1. Exclusion flowchart. The largest number of eligible patients used in the most inclusive models (models testing the signatures 172-GS, 3 clusters HPV and RSI with overall survival as the endpoint) is shown. See Figures S1, S2, S3 for exclusion flowcharts for other gene signature models.




Figure 2. Estimated relationship between the 172-GS signature and 2-year overall survival. a, b Estimated relationship in HPV-positive patients and HPV-negative patients, respectively. The signature score is scaled to a mean of 0 and a standard deviation of 1. Note the difference in sample size (N) per group. c, d Distribution of signature values in HPVpositive and HPV-negative patients, respectively.

831

832

833

834

835

836

837 838




Figure 3. Estimated relationship between the 3 clusters HPV signature and 2-year overall survival. a, b Estimated relationship in HPV-positive patients and HPV-negative patients, respectively. The signature score is scaled to a mean of 0 and a standard deviation of 1. Note the difference in sample size (N) per group. c, d Distribution of signature values in HPV-positive and HPV-negative patients, respectively.

841

842

843

844

845




Figure 4. Estimated relationship between the radiosensitivity index (RSI) and 2-year overall survival. a Relationship in patients that did not receive radiotherapy. b Relationship in patients that received radiotherapy. c Relationship in patients with missing information about radiotherapy treatment. The RSI score is scaled to a mean of 0 and a standard deviation of 1. Note the difference in sample size (N) per group.

Systemic treatment

856

857 858

859

860

861

862

863





Figure 5. Estimated relationship between the pancancer-cisplatin signature and 2-year overall survival. a Relationship in patients that received platinum-based chemotherapy. b Relationship in patients that received non-platinum based systemic treatment. c Relationship in patients that did not receive systemic treatment. d Relationship in patients with missing information about systemic treatment. The signature score is scaled to a mean of 0 and a standard deviation of 1. Note the difference in sample size (N) per group.



866 867

868

869 870

871

872




Figure 6. Estimated relationship between the Cl3-hypoxia signature and 2-year overall survival. a Relationship in patients that received cetuximab-based treatment. b Relationship in patients that received non-cetuximab based systemic treatment. c Relationship in patients that did not receive systemic treatment. **d** Relationship in patients with missing information about systemic treatment. The signature score is scaled to a mean of 0 and a standard deviation of 1. Note the difference in sample size (N) per group.